Monday, March 27, 2017
Breaking News

Atomoxetine (Strattera)

strateraStrattera is available by prescription in the United States.

Addictive Potential: Low

Emergency Room Visits Yearly: Unknown

Mandatory Minimum Sentence: Not Scheduled, Does Not Apply; Legal by Prescription

Mechanism of Action: Increases the Neurotransmitters Noreponephine and Dopamine

Overview:

Atomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). It is sold in the form of the hydrochloride salt of atomoxetine. It is manufactured and marketed under the brand name Strattera® by Eli Lilly and Company as a generic Attentin by Torrent Pharmaceuticals. There is currently no generic available within the United States due to patent restrictions.

Atomoxetine is classified as a norepinephrine reuptake inhibitor, and is approved for use in children, adolescents, and adults. However, its efficacy has not been studied in children under six years old. Its advantage over stimulants for the treatment of ADHD is that it has less abuse potential than stimulantsand is not scheduled as a controlled substance.

Strattera was originally intended to be a new antidepressant drug; however, in clinical trials, no such benefits could be proven. Since norepinephrine is believed to play a role in ADHD, Strattera was tested and subsequently approved as an ADHD treatment.

Leave a Reply